Deltamethrin
CAS 52918-63-5
Deltamethrin (CAS 52918-63-5) is a pharmaceutical compound with 1 bioactivity target and 25 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 24824.63846153846 nM | 13 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Deltamethrin used for in pharmaceutical contexts?
Deltamethrin (CAS 52918-63-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Deltamethrin?
Deltamethrin has 25 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Atrial fibrillation, Brain natriuretic peptide increased, Bronchospasm, Cardiac disorder, Chest discomfort. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Deltamethrin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Deltamethrin with EU status "prohibited".
What clinical phase is Deltamethrin in?
No phase 1-4 clinical development badge is rendered for Deltamethrin because the matched compound identifier rows do not contain a max-phase value.